Abstract
Sepsis is a complex disease associated with high morbidity and mortality. Early diagnosis, administration of appropriate antimicrobial therapy and source control are the cornerstones of treatment. The use of biomarkers to guide management of sepsis has been extensively investigated and is well described in the literature. However no single biomarker has been validated for the diagnosis of sepsis, prognostication or to guide antimicrobial prescribing. So their role in clinical practice is still unclear. An approach that integrates data from various combinations of biomarkers with the clinical information available at the bedside shows promise but requires further evaluation.